TW201713623A - １，２，３，４－四氫異喹啉衍生物、其製備方法和應用 - Google Patents

１，２，３，４－四氫異喹啉衍生物、其製備方法和應用 Download PDF

Info

Publication number
TW201713623A
TW201713623A TW105127662A TW105127662A TW201713623A TW 201713623 A TW201713623 A TW 201713623A TW 105127662 A TW105127662 A TW 105127662A TW 105127662 A TW105127662 A TW 105127662A TW 201713623 A TW201713623 A TW 201713623A
Authority
TW
Taiwan
Prior art keywords
group
membered
alkyl
cycloalkyl
substituted
Prior art date
Application number
TW105127662A
Other languages
English (en)
Chinese (zh)
Inventor
孫廣俊
馬建斌
譚松良
高鵬
李成海
包如迪
Original Assignee
上海翰森生物醫藥科技有限公司
江蘇豪森藥業集團有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海翰森生物醫藥科技有限公司, 江蘇豪森藥業集團有限公司 filed Critical 上海翰森生物醫藥科技有限公司
Publication of TW201713623A publication Critical patent/TW201713623A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105127662A 2015-08-29 2016-08-29 １，２，３，４－四氫異喹啉衍生物、其製備方法和應用 TW201713623A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510541474.1A CN106478502B (zh) 2015-08-29 2015-08-29 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用

Publications (1)

Publication Number Publication Date
TW201713623A true TW201713623A (zh) 2017-04-16

Family

ID=58186642

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105127662A TW201713623A (zh) 2015-08-29 2016-08-29 １，２，３，４－四氫異喹啉衍生物、其製備方法和應用

Country Status (3)

Country Link
CN (2) CN106478502B (fr)
TW (1) TW201713623A (fr)
WO (1) WO2017036318A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI647229B (zh) * 2017-11-14 2019-01-11 國立暨南國際大學 Method for synthesizing 3,4-hydroisoquinoline thiazolidine

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107778194B (zh) * 2016-08-24 2022-04-05 浙江九洲药业股份有限公司 一种苯丙氨酸酯化合物的制备及拆分方法
ES2878313T3 (es) 2017-06-09 2021-11-18 Shandong Danhong Pharmaceutical Co Ltd Derivado de ácido carboxílico como antagonista del receptor de AT2R
CN111620816B (zh) * 2020-05-27 2023-06-02 上海赛默罗生物科技有限公司 螺桨烷类衍生物、其制备方法、药物组合物和用途
CN111777555B (zh) * 2020-09-04 2020-12-01 上海赛默罗生物科技有限公司 脂肪环烷衍生物、其制备方法、药物组合物和其应用
WO2023160004A1 (fr) * 2022-02-25 2023-08-31 南京知和医药科技有限公司 Composé à cycle fusionné ayant une activité analgésique, son procédé de préparation et son utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
RS52927B (en) * 2004-12-24 2014-02-28 Spinifex Pharmaceuticals Pty Ltd TREATMENT OR PROPHYLAX PROCEDURE
NZ601383A (en) * 2010-01-19 2014-07-25 Spinifex Pharm Pty Ltd Methods and compositions for improved nerve conduction velocity
EP2595960B1 (fr) * 2010-07-21 2016-02-24 Novartis AG Sels et solvates d'un dérivé de tétrahydroisoquinoléine
CN105358532B (zh) * 2013-07-08 2019-07-23 诺华股份有限公司 杂环化合物和它们的使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI647229B (zh) * 2017-11-14 2019-01-11 國立暨南國際大學 Method for synthesizing 3,4-hydroisoquinoline thiazolidine

Also Published As

Publication number Publication date
CN107922340B (zh) 2020-07-10
CN106478502B (zh) 2021-04-27
CN107922340A (zh) 2018-04-17
CN106478502A (zh) 2017-03-08
WO2017036318A1 (fr) 2017-03-09

Similar Documents

Publication Publication Date Title
TW201713623A (zh) １，２，３，４－四氫異喹啉衍生物、其製備方法和應用
CN104470921B (zh) 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2020190774A1 (fr) Nouveaux inhibiteurs à petites molécules de facteurs de transcription tead
CN107108671B (zh) 作为raf激酶抑制剂的化合物和组合物
JP7021394B2 (ja) ニューロキニン－１受容体アンタゴニストとしての化合物およびその使用
JP2022512900A (ja) アセチル化ライター阻害剤の開発およびその使用
KR20180080245A (ko) 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법
CN108495618A (zh) 新的化合物及其用途
CN104169287A (zh) 作为促性腺激素释放激素受体拮抗剂的螺二氢吲哚衍生物
EP3700891A1 (fr) Dérivés sulfonamides aromatiques pour le traitement d'un accident cérébral ischémique
EP3204374B1 (fr) Dérivés d'isoindoline
JP6970684B2 (ja) クマリン骨格を有するスルホンアミド誘導体
CN110023310A (zh) 用于调节激酶级联的联芳组合物和方法
AU2015308438B2 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
JP2011510062A (ja) 置換された２−アミノ−３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用
JP5690594B2 (ja) ３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用
WO2016064682A1 (fr) Inhibiteurs sélectifs du récepteur constitutif des androstanes
CN110963957A (zh) N-芳香酰胺类化合物及其制备方法和用途
EP4286390A1 (fr) Dérivé d'amide hétérocyclique, son procédé de préparation et son utilisation
BRPI0620526A2 (pt) sal de acetato e método para alcançar um efeito em um paciente
WO2022033416A1 (fr) Composé cyclique condensé utilisé en tant qu'inhibiteur d'egfr, son procédé de préparation et son utilisation
CN107304199B (zh) 一种新的喜巴辛类似物及其在医药中的应用
BR112021004094A2 (pt) formas cristalinas de um inibidor de fosfoinositídeo 3-quinase (pi3k)
WO2019163865A1 (fr) Dérivé de dibenzazépine ayant un cycle hétérocyclique contenant de l'azote
TW202340145A (zh) 氘化有機化合物及其用途